DermRx.
← All drugs

ixekizumab

Taltz

Modality
mAb (humanized IgG4)
Mechanism
IL-17A neutralization
Targets
IL-17A
Storage
refrigerated 2–8 °C
Approved
plaque psoriasis — FDA 2016 · psoriatic arthritis — FDA 2017 · ankylosing spondylitis — FDA 2019
In trial
—
Monitoring
TB, IBD screening
Sources
DailyMed (FDA label)DrugBankClinicalTrials.gov
Last verified
2026-04-14
No curated MOA diagram yet. See lib/moa-data.ts for the shape; add an entry keyed by ixekizumab.

Monitoring & workup

Baseline workup

  • •TB IGRA (or PPD)
  • •HBV sAg if high risk; HCV Ab if high risk
  • •Update age-appropriate vaccines before start

Ongoing monitoring

  • •No routine labs
  • •Annual TB screening if high exposure risk
  • •IL-17 class: monitor for candida overgrowth + IBD flare
  • •IL-23 class: monitor for injection-site reactions